Epigallocatechin-3-gallate (EGCG)

DRUG5 trials

Sponsors

Parc de Salut Mar, Florian Michel, Hal Chapman, University of Rochester

Conditions

Cardiac InvolvementDown SyndromeDown Syndrome (DS)FrailtyIdiopathic Pulmonary FibrosisInflammationLight Chain (AL) Amyloidosis

Early Phase 1

Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.

CompletedNCT03928847

Hal ChapmanIdiopathic Pulmonary Fibrosis

Start: 2017-12-01End: 2019-05-31Updated: 2022-12-22

Phase 2

Egcg, a dyrk1a Inhibitor as Therapeutic Tool for Reversing Cognitive Deficits in Down Syndrome Individuals.

CompletedNCT01394796

Parc de Salut MarDown Syndrome

Start: 2010-05-31End: 2011-02-28Updated: 2013-03-13

Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool

CompletedNCT01699711

Parc de Salut MarDown Syndrome (DS)

Start: 2012-02-29End: 2015-03-31Updated: 2016-02-11

A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)

CompletedNCT02015312

Florian MichelCardiac Involvement, Light Chain (AL) Amyloidosis

Start: 2013-04-30End: 2017-10-11Updated: 2017-10-17

Reducing Frailty for Older Cancer Survivors Using Supplements II

SuspendedNCT06068543

University of RochesterFrailty, Inflammation

Start: 2024-10-25End: 2030-12-31Target: 118Updated: 2026-06-26

Related Papers

Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial.

2016-07-01212 citations